Podium Session 1: Prostate Cancer June 26, 2016 1050–1150

ABSTRACT: Introduction and Objectives: The phase 2 TERRAIN trial compared the efficacy and safety of enzalutamide (ENZA) vs. bicalutamide (BIC) in patients (pts) with metastatic castration-resistant prostate cancer who had progressed on luteinizing hormone-releasing hormone agonist/antagonist therapy or after bilateral orchiectomy while maintaining castration therapy during the study. An age effect analysis was pre-specified to investigate the efficacy and safety of ENZA vs. BIC. Results are presented in younger (<75 years) and older (≥75 years) pts in the TERRAIN population. Methods: In this double-blind study in North America and Europe, pts were randomized 1:1 to ENZA 160 mg/day or BIC 50 mg/day. The primary efficacy endpoint was centrally assessed progression-free survival (PFS) and a secondary

SUBMITTER:  

PROVIDER: S-EPMC5413364 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature